The intravenous injection of oxidized LDL- or Apolipoprotein B100 - Coupled splenocytes promotes Th1 polarization in wildtype and Apolipoprotein E - Deficient mice

Biochemical and Biophysical Research Communications

Volumn 464, Issue 1, 2015, Pages 306-311

  Steinmetz, Martin ^a,b   Ponnuswamy, Padmapriya ^a   Laurans, Ludivine ^a   Esposito, Bruno ^a   Tedgui, Alain ^a   Mallat, Ziad ^a,c  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Apolipoprotein B100; Apolipoprotein E deficient mice; Atherosclerosis; ECDI; Immunization; LDL

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN E; GAMMA INTERFERON; OXIDIZED LOW DENSITY LIPOPROTEIN; CYANAMIDE; LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL POLARITY; CELL PROLIFERATION; CELL THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; EXPERIMENTAL ATHEROSCLEROSIS; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TRANSGENIC MOUSE; WILD TYPE MOUSE; ANIMAL; ATHEROSCLEROSIS; BIOLOGICAL THERAPY; BIOSYNTHESIS; CHEMISTRY; CYTOLOGY; DEFICIENCY; DISEASE MODEL; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KNOCKOUT MOUSE; LYMPHOCYTE; LYMPHOCYTE TRANSFUSION; MACROPHAGE; MONOCYTE; PATHOLOGY; PLAQUE, ATHEROSCLEROTIC; SECRETION (PROCESS); SPLEEN; TRANSPLANTATION; TREATMENT FAILURE;

MURINAE; MUS; MUS MUSCULUS;

ANIMALS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CARBODIIMIDES; CELL- AND TISSUE-BASED THERAPY; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; INJECTIONS, INTRAVENOUS; INTERFERON-GAMMA; LIPOPROTEINS, LDL; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; MONOCYTES; PLAQUE, ATHEROSCLEROTIC; SPLEEN; TH1 CELLS; TREATMENT FAILURE;

EID: 84937637274     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.06.148     Document Type: Article

References (29)

1. A. Tedgui, and Z. Mallat Cytokines in atherosclerosis: pathogenic and regulatory pathways Physiol. Rev. 86 2006 515 581
2. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
3. Z. Mallat, S. Taleb, H. Ait-Oufella, and A. Tedgui The role of adaptive T cell immunity in atherosclerosis J. Lipid Res. 50 Suppl 2009 S364 S369
4. G. Paulsson, X. Zhou, E. Törnquist, and G.K. Hansson Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice Arterioscler. Thromb. Vasc. Biol. 20 2000 10 17
5. X. Zhou, A.-K.L. Robertson, M. Rudling, P. Parini, and G.K. Hansson Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis Circ. Res. 96 2005 427 434
6. K. Tse, A. Gonen, J. Sidney, H. Ouyang, J.L. Witztum, and et al. Atheroprotective vaccination with MHC-II restricted peptides from ApoB-100 Front. Immunol. 4 2013 493
7. J. Khallou-Laschet, E. Tupin, G. Caligiuri, B. Poirier, N. Thieblemont, and et al. Atheroprotective effect of adjuvants in apolipoprotein E knockout mice Atherosclerosis 184 2006 330 341
8. O. Herbin, H. Ait-Oufella, W. Yu, G.N. Fredrikson, B. Aubier, and et al. Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice Arterioscler. Thromb. Vasc. Biol. 32 2012 605 612
9. L. Chen, and D.B. Flies Molecular mechanisms of T cell co-stimulation and co-inhibition Nat. Rev. Immunol. 13 2013 227 242
10. D.R. Getts, S. Shankar, E.M.L. Chastain, A. Martin, M.T. Getts, and et al. Current landscape for T-cell targeting in autoimmunity and transplantation Immunotherapy 3 2011 853 870
11. J.R. Podojil, and S.D. Miller Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy Immunol. Rev. 229 2009 337 355
12. S.D. Miller, D.M. Turley, and J.R. Podojil Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease Nat. Rev. Immunol. 7 2007 665 677
13. D.R. Getts, D.P. McCarthy, and S.D. Miller Exploiting apoptosis for therapeutic tolerance induction J. Immunol. 191 2013 5341 5346
14. A.A. Vandenbark, D. Barnes, T. Finn, D.N. Bourdette, R. Whitham, and et al. Differential susceptibility of human T(h)1 versus T(h) 2 cells to induction of anergy and apoptosis by ECDI/antigen-coupled antigen-presenting cells Int. Immunol. 12 2000 57 66
15. X. Luo, K.C. Herold, and S.D. Miller Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity 32 2010 488 499
16. D.M. Turley, and S.D. Miller Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis J. Immunol. 178 2007 2212 2220
17. L.M. Godsel, K. Wang, B.A. Schodin, J.S. Leon, S.D. Miller, and et al. Prevention of autoimmune myocarditis through the induction of antigen-specific peripheral immune tolerance Circulation 103 2001 1709 1714
18. G. Chen, T. Kheradmand, J. Bryant, S. Wang, J. Tasch, and et al. Intragraft CD11b(+) IDO(+) cells mediate cardiac allograft tolerance by ECDI-fixed donor splenocyte infusions Am. J. Transpl. 12 2012 2920 2929
19. M. Niens, A.E. Grier, M. Marron, T.W.H. Kay, D.L. Greiner, and et al. Prevention of Humanized diabetogenic CD8 T-cell responses in HLA-transgenic NOD mice by a multipeptide coupled-cell approach Diabetes 60 2011 1229 1236
20. C.B. Smarr, C.-L. Hsu, A.J. Byrne, S.D. Miller, and P.J. Bryce Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy J. Immunol. 187 2011 5090 5098
21. A. Lutterotti, and S. Yousef Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis Sci. Transl. 5 2013 1 21
22. K. Radulovic, C. Manta, V. Rossini, K. Holzmann, H.a. Kestler, and et al. CD69 regulates type I IFN-induced tolerogenic signals to mucosal CD4 T cells that attenuate their colitogenic potential J. Immunol. 188 2012 2001 2013
23. M.L.F. Smook, M. van Leeuwen, P. Heeringa, J.G.M.C. Damoiseaux, R. Theunissen, and et al. Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE and APOECD40L mice Clin. Exp. Immunol. 154 2008 264 269
24. X. Zhou, A.-K.L. Robertson, C. Hjerpe, and G.K. Hansson Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis Arterioscler. Thromb. Vasc. Biol. 26 2006 864 870
25. C.J. Binder, K. Hartvigsen, M.-K. Chang, M. Miller, D. Broide, and et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis J. Clin. Invest. 114 2004 427 437
26. K. Tse, A. Gonen, J. Sidney, H. Ouyang, J.L. Witztum, and et al. Atheroprotective vaccination with MHC-II restricted peptides from ApoB-100 Front. Immunol. 4 2013 493
27. J.Z. Oh, R. Ravindran, B. Chassaing, F.A. Carvalho, M.S. Maddur, and et al. Article TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination Immunity 41 2014 478 492
28. H. Ait-Oufella, S. Taleb, Z. Mallat, and A. Tedgui Cytokine network and T cell immunity in atherosclerosis Semin. Immunopathol. 31 2009 23 33
29. H.M. Dansky, S.a. Charlton, M.M. Harper, and J.D. Smith T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse Proc. Natl. Acad. Sci. U. S. A. 94 1997 4642 4646